DEXLOCID^® 30

Proton pump inhibitors

Dexlansoprazole

Dexlocid delayed-release capsule is a Proton Pump Inhibitor (PPI) that inhibits gastric acid secretion. Dexlocid is the R-enantiomer of lansoprazole (Aracemic mixture of the R- & S-enantiomers). Dexlocid is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. Dexlocid capsule contains a mixture of two types of enteric coated pellets with different pH-dependent dissolution profiles.

Dosage form: Capsule
Strength: 30 mg
Composition: Each capsule contains Dexlansoprazole INN 30 mg as enteric coated pellets.
Pack sizes: Each box contains 6x10's Capsules in Alu-Alu blister pack.

Manufactured by Doctor's Chemical Works Ltd.

Prescribing information

Pharmacokinetics

The formulation of Dexlansoprazole utilizing Dual Delayed Release technology results in plasma concentration- time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. No accumulation of Dexlansoprazole occurs after multiple once daily doses of Dexlansoprazole 30 mg. After oral administration of Dexlansoprazole 30 mg or 60 mg to healthy subjects, mean C max and AUC values of Dexlansoprazole increased approximately dose proportionally. Dexlansoprazole is extensively metabolized in the liver and excreted by urine.